Floretyrosine F not checked
Telix Pharmaceuticals (Innovations) Pty Limited
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Floretyrosine F 18 (\[18F\]FET) is an investigational amino acid positron emission tomography (PET) radiopharmaceutical administered as a single intravenous injection for diagnostic imaging. Participants in Part 1 receive 740 MBq (±10%) of \[18F\]FET to evaluate dose optimization through comparison of reconstructed reduced-dose and full-dose PET images. Participants in Part 2 receive \[18F\]FET…”In the company’s words, NCT07931261 on ClinicalTrials.gov
- Tested for
- Brain Metastasis, Radiation Necrosis, Pseudoprogression, Tumor Progression
- Main trialPhase 3
- “This Phase 3 study will evaluate whether \[18F\]Floretyrosine (\[18F\]FET) PET imaging can help distinguish active brain tumor growth from treatment-related changes in patients with brain metastases who have unclear MRI findings after treatment. The study has two parts. Part 1 will identify the lowest effective dose of \[18F\]FET PET that provides reliable imaging results. Part 2 will evaluate the accuracy of \[18F\]FET PET, using the optimized dose, for distinguishing tumor progression from treatment-related changes. Study results will be compared with information from follow-up imaging,…”In the company’s words, NCT07931261 on ClinicalTrials.gov
Coming up1
- Apr 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07931261
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Apr 2028 | [18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026